Xenotransplantation Market Report 2026

The xenotransplantation market size has grown strongly in recent years. It will grow from $15.77 billion in 2025 to $17.13 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to advancements in organ preservation science, shortage of human donor organs, progress in immunosuppressive therapies, early-stage xenograft research programs, development of transplant diagnostic technologies.

The xenotransplantation market size is expected to see strong growth in the next few years. It will grow to $23.51 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing clinical trial activity in xenotransplantation, rising investments in gene-editing technologies, growing collaboration between biotech firms and hospitals, expansion of ethical and regulatory acceptance, increasing demand for alternative organ sources. Major trends in the forecast period include increasing research in genetically modified donor organs, growing focus on immune rejection mitigation, expansion of advanced organ preservation technologies, rising investment in translational transplant research, improved regulatory frameworks for clinical trials.

The rising demand for tissue and organ transplantation is expected to drive the growth of the xenotransplantation market. Hereditary disorders such as polycystic kidney disease, cystic fibrosis, or heart defects often create a high need for organ transplants among affected individuals. This strong demand has led to a significant shortage of human organs. Xenotransplantation addresses this gap by using nonhuman organs as alternatives to human donors. For instance, in January 2024, according to the Organ Procurement and Transplantation Network (OPTN), a US-based program under the Department of Health and Human Services overseeing the nation’s organ donation and transplantation system, a total of 46,632 organ transplants from living and deceased donors were performed in 2023, reflecting an 8.7% increase compared with 2022. Of these, 39,679 procedures involved deceased donors, representing an 8.9% rise over the previous year. Therefore, the increasing need for tissue and organ transplantation is fueling the growth of the xenotransplantation market.

Key companies in the xenotransplantation market are focusing on strategic partnerships to deliver reliable solutions. A strategic partnership is a formal collaboration between two or more organizations to achieve mutual goals or complement each other’s capabilities. For instance, in April 2023, Karius, a US-based leader in liquid biopsy for infectious diseases, partnered with eGenesis, Inc., a US-based biotechnology firm pioneering xenotransplantation, to develop human-compatible organs and cells for treating organ failure. This collaboration aims to alleviate organ shortages and accelerate the availability of safe xenotransplantation. Karius will use its platform to detect and measure diseases potentially present in porcine organ donors, while the partnership will establish a comprehensive testing system for microbial cell-free DNA, supporting pre- and post-transplant monitoring.

In October 2023, United Therapeutics Corporation, a US-based biotechnology company, acquired Miromatrix Medical for $91 million. The acquisition expands United Therapeutics’ organ production initiatives, including xenotransplantation, 3D bioprinting, x-vivo lung perfusion, and regenerative medicine techniques. Miromatrix Medical is a US-based development-stage company producing fully implantable manufactured kidney products.

Major companies operating in the xenotransplantation market are United Therapeutics, Preservation Solutions, OrganOX Limited, Talaris Therapeutics, TransMedic Inc., Sernova Corp, Nova Lung, Recombinetics, Tissue Regenix, TissueGene, SAB Biotherapeutics, eGenesis, Revivicor, Organ Recovery Systems, CRISPR Therapeutics, Qihan Biotech, Sino-Clone Organ Biotechnology, Xenothera, Lung Biotechnology.

North America was the largest region in the xenotransplantation market in 2025. The regions covered in the xenotransplantation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xenotransplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the xenotransplantation market by increasing costs of imported laboratory equipment, genetic engineering tools, bioprocessing systems, and advanced diagnostic instruments. Research institutions and transplant centers in North America and Europe are most affected due to reliance on specialized imported technologies, while Asia-Pacific faces cost pressure on preclinical research materials. These tariffs are raising research and development expenditures and extending clinical timelines. However, they are also encouraging domestic innovation, localized manufacturing of research tools, and stronger regional biotech ecosystems supporting long-term advancement.

The xenotransplantation market research report is one of a series of new reports that provides xenotransplantation market statistics, including xenotransplantation industry global market size, regional shares, competitors with a xenotransplantation market share, detailed xenotransplantation market segments, market trends and opportunities, and any further data you may need to thrive in the xenotransplantation industry. This xenotransplantation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Xenotransplantation is a medical procedure in which live nonhuman animal cells, tissues, or organs are transplanted, implanted, or infused into a human recipient. It also encompasses the transplantation, implantation, or infusion of human body fluids, cells, tissues, or organs that have had ex vivo contact with living nonhuman animal cells, tissues, or organs.

The primary products of xenotransplantation are organ preservation solutions, transplant diagnostics, and tissue products. Organ preservation solutions help reduce ischemic and hypoxic damage during cold storage and improve graft survival. Techniques in this field include machine perfusion, in situ core cooling, and the use of organ preservation fluids. Xenotransplantation treatments also involve analgesics, immunosuppressants, and other therapies for organs such as the heart, kidneys, and more. The end users include hospitals, transplant centers, and other healthcare facilities.

The xenotransplantation market includes revenues earned by entities by providing transplantation and diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.